DIabetes GLycemic Assessment in Newly Confirmed Episodes

Inclusion Criteria: * Age of 18 years and older. * Newly diagnosed Type 2 Diabetes Mellitus according to ADA (American Diabetes Association) criteria (Fasting Plasma Glucose ≥ 7.0 mmol/L, or 2-hour Post-Prandial Glucose ≥ 11.1 mmol/L during OGTT, or HbA1c ≥6.5%). * Time since the initial diagnosis of T2D must not exceed 3 months ( less 90 days) at the time of screening. * HbA1c level between 6.5% and 9.5% (inclusive) at screening. * Patients may be lifestyle-controlled or receiving any stable non-insulin anti-diabetic therapy (including Metformin, SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, or Sulfonylureas) as monotherapy or combination therapy. * Ability to provide written informed consent and willingness to adhere to the study protocol and follow-up schedule. Exclusion Criteria: * Diagnosis or suspicion of Type 1 Diabetes, Latent Autoimmune Diabetes in Adults (LADA) (e.g., positive anti-GAD antibodies if tested), or secondary types of diabetes (e.g., pancreatic or drug-induced). * Any prior or current use of insulin therapy. * Severe microvascular or macrovascular complications (proliferative retinopathy, severe diabetic nephropathy with eGFR \< 45 mL/min/1.73m², diabetic foot ulcers, severe peripheral neuropathy). * Endocrine disorders (e.g., Itsenko-Cushing syndrome, acromegaly) that affect glycemia. * History of myocardial infarction, stroke, unstable angina, coronary artery bypass graft (CABG), or percutaneous coronary intervention (PCI) within the past 6 months. * Active malignancy, decompensated heart failure (NYHA Class III or IV), or chronic infectious diseases. * Pregnant or breastfeeding women, or women of childbearing potential not using highly effective contraception. * Has evidence of current abuse of drugs or alcohol or a history of abuse that, in the investigator's opinion, would cause the individual to be noncompliant. * Participation in another clinical study within the last 3 months.